Apellis Pharmaceuticals (APLS) Competitors $17.98 +0.17 (+0.93%) Closing price 03:48 PM EasternExtended Trading$17.93 -0.05 (-0.31%) As of 04:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock APLS vs. BPMC, BBIO, VRNA, ROIV, RVMD, ELAN, LEGN, TGTX, GRFS, and LNTHShould you be buying Apellis Pharmaceuticals stock or one of its competitors? The main competitors of Apellis Pharmaceuticals include Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Apellis Pharmaceuticals vs. Its Competitors Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Revolution Medicines Elanco Animal Health Legend Biotech TG Therapeutics Grifols Lantheus Apellis Pharmaceuticals (NASDAQ:APLS) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk. Do analysts prefer APLS or BPMC? Apellis Pharmaceuticals currently has a consensus price target of $39.79, indicating a potential upside of 121.24%. Blueprint Medicines has a consensus price target of $128.06, indicating a potential downside of 0.16%. Given Apellis Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Blueprint Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 2.62Blueprint Medicines 0 Sell rating(s) 17 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.27 Do institutionals and insiders believe in APLS or BPMC? 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 6.5% of Apellis Pharmaceuticals shares are held by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, APLS or BPMC? Apellis Pharmaceuticals has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Which has higher valuation & earnings, APLS or BPMC? Blueprint Medicines has lower revenue, but higher earnings than Apellis Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApellis Pharmaceuticals$781.37M2.89-$197.88M-$1.79-10.05Blueprint Medicines$508.82M16.28-$67.09M-$2.47-51.93 Is APLS or BPMC more profitable? Blueprint Medicines has a net margin of -27.70% compared to Apellis Pharmaceuticals' net margin of -28.83%. Blueprint Medicines' return on equity of -64.60% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Apellis Pharmaceuticals-28.83% -99.19% -25.35% Blueprint Medicines -27.70%-64.60%-17.22% Does the media favor APLS or BPMC? In the previous week, Apellis Pharmaceuticals had 11 more articles in the media than Blueprint Medicines. MarketBeat recorded 18 mentions for Apellis Pharmaceuticals and 7 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.84 beat Apellis Pharmaceuticals' score of 0.53 indicating that Blueprint Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apellis Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Blueprint Medicines 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryApellis Pharmaceuticals beats Blueprint Medicines on 9 of the 16 factors compared between the two stocks. Get Apellis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLS vs. The Competition Export to ExcelMetricApellis PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.24B$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-10.0521.4227.3820.03Price / Sales2.89285.81422.31120.16Price / CashN/A41.9536.6357.47Price / Book9.777.518.085.67Net Income-$197.88M-$55.05M$3.16B$248.47M7 Day Performance-2.26%3.16%2.12%2.90%1 Month Performance-4.44%5.92%4.43%5.75%1 Year Performance-49.21%5.82%35.62%21.36% Apellis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLSApellis Pharmaceuticals4.5199 of 5 stars$17.99+0.9%$39.79+121.2%-49.1%$2.24B$781.37M-10.05770Trending NewsAnalyst ForecastAnalyst RevisionBPMCBlueprint Medicines1.7239 of 5 stars$128.40+0.2%$128.06-0.3%+16.2%$8.29B$508.82M-51.98640High Trading VolumeBBIOBridgeBio Pharma4.706 of 5 stars$42.17+1.1%$56.67+34.4%+71.9%$8.01B$127.42M-11.95400News CoverageAnalyst ForecastInsider TradeAnalyst RevisionVRNAVerona Pharma PLC American Depositary Share2.6433 of 5 stars$97.05+2.9%$101.10+4.2%+482.7%$7.87B$118.54M-48.5330Positive NewsAnalyst ForecastROIVRoivant Sciences1.9559 of 5 stars$11.50+0.4%$17.50+52.2%+3.9%$7.82B$29.05M-46.00860RVMDRevolution Medicines4.5755 of 5 stars$40.04+1.0%$67.08+67.5%-0.5%$7.46B$11.58M-10.01250Analyst RevisionELANElanco Animal Health2.2418 of 5 stars$13.36-0.7%$15.17+13.5%+5.1%$6.64B$4.43B18.059,000Analyst ForecastLEGNLegend Biotech3.2607 of 5 stars$33.85-0.4%$76.20+125.1%-19.7%$6.22B$627.24M-57.372,609News CoverageAnalyst ForecastTGTXTG Therapeutics3.1586 of 5 stars$36.56+1.5%$40.80+11.6%+98.2%$5.80B$329M152.33290GRFSGrifols4.0481 of 5 stars$8.37-4.6%$10.30+23.1%+40.2%$5.75B$7.81B7.1523,822LNTHLantheus4.4562 of 5 stars$80.81+2.0%$130.50+61.5%+1.4%$5.59B$1.53B22.96700 Related Companies and Tools Related Companies BPMC Alternatives BBIO Alternatives VRNA Alternatives ROIV Alternatives RVMD Alternatives ELAN Alternatives LEGN Alternatives TGTX Alternatives GRFS Alternatives LNTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apellis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apellis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
